| T36287 |
Pirtobrutinib
|
2101700-15-4
|
98%
|
|
|
Pirtobrutinib (LOXO-305) is an advanced BTK inhibitor that displays high selectivity and operates through a non-covalent mechanism. This compound effectively inh...
|
| T39707 |
AS-1763
|
2227211-00-7
|
98%
|
|
|
AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.
|
| T6918 |
Olmutinib
|
1353550-13-6
|
98%
|
|
|
Olmutinib (HM61713, BI 1482694) is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential ant...
|
| T14692 |
BMX-IN-1
|
1431525-23-3
|
|
|
|
BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine kina...
|
| T9705 |
TL-895
|
1415823-49-2
|
|
|
|
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton’s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and...
|
| T4268 |
CHMFL-BMX-078
|
1808288-51-8
|
|
|
|
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
|
| T3024 |
Avitinib
|
1557267-42-1
|
100%
|
|
|
Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, wi...
|
| T17220 |
Vecabrutinib
|
1510829-06-7
|
100%
|
|
|
Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.
|
| T4391 |
Syk Inhibitor II dihydrochloride
|
227449-73-2
|
100%
|
|
|
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ chain...
|
| T5407 |
Branebrutinib
|
1912445-55-6
|
95.86%
|
|
|
Branebrutinib (BMS986195) is a potent, covalent inhibitor of Bruton's tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC...
|
| T9408 |
N-piperidine Ibrutinib
|
330785-90-5
|
96.65%
|
|
|
N-piperidine Ibrutinib is a potent BTK inhibitor with IC50s of 51.0 for WT BTK and 30.7 nM for C481S BTK respectively. N-piperidine Ibrutinib can be used as a BT...
|
| T67881 |
Acalabrutinib enantiomer
|
1952316-43-6
|
96.68%
|
|
|
Acalabrutinib enantiomer (R-Acalabrutinib) is a chemical compound that belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors. Acarabitinib enantiomer...
|
| T16157 |
MT-802
|
2231744-29-7
|
97%
|
|
|
MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).
|
| T13564 |
AZ7550
|
1421373-99-0
|
97.07%
|
|
|
AZ7550, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
|
| T2603 |
Spebrutinib
|
1202757-89-8
|
97.14%
|
|
|
Spebrutinib (LMK-435) is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity...
|
| T6078 |
Saracatinib
|
379231-04-6
|
98.03%
|
|
|
Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
|
| T4387 |
Evobrutinib
|
1415823-73-2
|
98.04%
|
|
|
Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the deve...
|
| T13447 |
(R)-Zanubrutinib
|
1691249-44-1
|
98.04%
|
|
|
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
|
| T9192 |
BIIB068
|
1798787-27-5
|
98.05%
|
|
|
BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases.
|
| T64124 |
Sunvozertinib
|
2370013-12-8
|
98.11%
|
|
|
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inh...
|
